Application of vortioxetine in outpatients with endogenous depression

Abstract

The study aimed to evaluate the clinical action, safety, and tolerability of vortioxetine in outpatients with depressive conditions.

Material and methods. An open comparative study of patients with various nosological forms of endogenous depressive conditions (depressive episodes, recurrent depressive disorder, and bipolar affective disorder) was conducted. The course of therapy with vortioxetine in a daily dose of 10–20 mg lasted 42 days. Methods of clinical and psychometric evaluation of the results were used as well as correlation analysis using Spearman’s coefficient. The severity and degree of reduction in depressive and anxiety symptoms were recorded using the Hamilton Depression Scale (HAM-D), the Hamilton Anxiety Scale (HAM-A), and the Clinical Global Impression–Disease Severity Scale (CGI-S). To assess the severity of adverse side effects, the side effects rating scale (UKU) was used.

Results. Vortioxetine has been found to be an effective antidepressant. At the end of therapy, a reduction in the mean total score on the HAM-D scale by more than 50% was registered in 92.2% of patients. Furthermore, 76.3% of patients had a therapeutic effect with a reduction in the mean total scores of the HAM-D scale by more than 80%. The reduction in mean scores on the HAM-A scale by day 28 reached 87.25%. According to the CGI-S scale values, 68.4% of patients completed the course of therapy with complete remission. Significant direct correlations were found between the daily drug dose and disease duration and the initial depressive symptom severity. A correlation between the anxiety level and vortioxetine dose was observed in all stages of therapy. The depression level on days 7 and 21 correlated with the dose size, starting from week 3. The adverse event severity detected in most cases ranged from mild to moderate.

Conclusion. Thymoanaleptic and anxiolytic activities provide vortioxetine with efficacy in various nosological forms of endogenous depression. For conditions with a longer duration and severity of the disease, a higher dosage of vortioxetine (20 mg/day) is required. During therapy, vortioxetine has demonstrated a favorable safety and tolerability profile; therefore, it can be used in an outpatient basis.

Keywords

vortioxetine / endogenous depression / schizotypal disorder / disorders of the affective range

References

[1] Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, et al. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess. 2018;22(63):1–136. doi: 10.3310/hta22630.

[2] Kessler D., Burns A., Tallon D., Lewis G., MacNeill S., Round J., et al. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT // Health Technol Assess. 2018. Vol. 22. N 63. P. 1–136. doi: 10.3310/hta22630.

[3] McClintock HF, BeKampis AN, Hartmann E, Bogner HR. Adherence to antidepressants in underserved communities: a comparison of electronic monitoring and self-report measures. Neuropsychiatr Dis Treat. 2019;15:1249–1258. doi: 10.2147/NDT.S199746.

[4] McClintock H.F., BeKampis A.N., Hartmann E., Bogner H.R. Adherence to antidepressants in underserved communities: a comparison of electronic monitoring and self-report measures // Neuropsychiatr Dis Treat. 2019. Vol. 15. P. 1249–1258. doi: 10.2147/NDT.S199746.

[5] Jha MK. Discontinuing antidepressants: how can clinicians guide patients and drive research? J Clin Psychiatry. 2019;80(6):19com13047. doi: 10.4088/JCP.19com13047.

[6] Jha M.K. Discontinuing antidepressants: how can clinicians guide patients and drive research? // J Clin Psychiatry. 2019. Vol. 80. N 6. P. 19com13047. doi: 10.4088/JCP.19com13047.

[7] Smith R, Khalsa SS, Paulus MP. An active inference approach to dissecting reasons for nonadherence to antidepressants. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;S2451-9022(19)30309-X. doi: 10.1016/j.bpsc.2019.11.012.

[8] Smith R., Khalsa S.S., Paulus M.P. An active inference approach to dissecting reasons for nonadherence to antidepressants // Biol Psychiatry Cogn Neurosci Neuroimaging. 2019. P. S2451-9022(19)30309-X. doi: 10.1016/j.bpsc.2019.11.012.

[9] Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249–1258. doi: 10.2147/NDT.S199746. eCollection 2019.

[10] Perini G., Cotta Ramusino M., Sinforiani E., Bernini S., Petrachi R., Costa A. Cognitive impairment in depression: recent advances and novel treatments // Neuropsychiatr Dis Treat. 2019. Vol. 15. P. 1249–1258. doi: 10.2147/NDT.S199746. eCollection 2019.

[11] Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin. 2020;36(5):875–882. doi: 10.1080/03007995.2020.1723072.

[12] Wang G., Zhao K., Reynaud-Mougin C., Loft H., Ren H., Eriksen H.F., Ettrup A. Successfully treated patient.with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in asian patients with major depressive disorder // Curr Med Res Opin. 2020. Vol. 36. N 5. P. 875–882. doi: 10.1080/03007995.2020.1723072.

[13] Inoue T, Sasai K, Kitagawa T. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci. 2020;74(2):140–148. doi: 10.1111/pcn.12956.

[14] Inoue T., Sasai K., Kitagawa T. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder // Psychiatry Clin Neurosci. 2020. Vol. 74. N 2. P. 140–148. doi: 10.1111/pcn.12956.

[15] Orsolini L, Tomasetti C, Valchera A, Iasevoli F. Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine. CNS Neurol Disord Drug Targets. 2017;16(1):65–92. doi: 10.2174/1871527315666161025140111.

[16] Orsolini L., Tomasetti C., Valchera A., Iasevoli F. Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine // CNS Neurol Disord Drug Targets. 2017. Vol. 16. N 1. P. 65–92. doi: 10.2174/1871527315666161025140111.

[17] Chilmonczyk Z, Bojarski AJ, Pilc A, Sylte I. Functional selectivity and antidepressant activity of serotonin 1a receptor ligands. Int J Mol Sci. 2015;16(8):18474–18506. doi: 10.3390/ijms160818474.

[18] Chilmonczyk Z., Bojarski A.J., Pilc A., Sylte I. Functional selectivity and antidepressant activity of serotonin 1a receptor ligands // Int J Mol Sci. 2015. Vol. 16. N 8. P. 18474–18506. doi: 10.3390/ijms160818474.

[19] Dale E, Pehrson AL, Jeyarajah Т, Li Y. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. CNS Spectr. 2016;21(2):143–161. doi: 10.1017/S1092852915000425.

[20] Dale E., Pehrson A.L., Jeyarajah Т., Li Y. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function // CNS Spectr. 2016. Vol. 21. N 2. P. 143–161. doi: 10.1017/S1092852915000425.

[21] Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686. doi: 10.1007/s40262-017-06127.

[22] Chen G., Højer A.M., Areberg J., Nomikos G. Vortioxetine: clinical pharmacokinetics and drug interactions // Clin Pharmacokinet. 2018. Vol. 57. N 6. P. 673–686. doi: 10.1007/s40262-017-06127.

[23] David DJ, Tritschler L, Guilloux JP, Gardier AM. Pharmacological properties of vortioxetine and its pre-clinical consequences. Encephale. 2016;42(Suppl 1):1S12–23. doi: 10.1016/S0013-7006(16)30015-X.

[24] David D.J., Tritschler L., Guilloux J.P., Gardier A.M. Pharmacological properties of vortioxetine and its pre-clinical consequences // Encephale. 2016. Vol. 42. N Suppl 1. P. 1S12–23. doi: 10.1016/S0013-7006(16)30015-X.

[25] Bardenstein LM. Neurotransmitters and depression. Rossiiskii psikhiatricheskii zhurnal. 2004;(2):137–143. (In Russ).

[26] Барденштейн Л.М. Нейромедиаторы и депрессия // Российский психиатрический журнал. 2004. № 2. C. 137–143.

[27] Ladefoged LK, Munro L, Pedersen AJ. Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT3A receptor. Mol Pharmacol. 2018;94(6):1421–1434. doi: 10.1124/mol.118.113530.

[28] Ladefoged L.K., Munro L., Pedersen A.J. Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT3A receptor // Mol Pharmacol. 2018. Vol. 94. N 6. P. 1421–1434. doi: 10.1124/mol.118.113530.

[29] Pytka K, Głuch-Lutwin M, Żmudzka E. HBK-17, a 5-HT1A receptor ligand with anxiolytic-like activity, preferentially activates ß-arrestin signaling. Front Pharmacol. 2018;(9):1146. doi: 10.3389/fphar.2018.01146.

[30] Pytka K., Głuch-Lutwin M., Żmudzka E. HBK-17, a 5-HT1A receptor ligand with anxiolytic-like activity, preferentially activates ß-arrestin signaling // Front Pharmacol. 2018. N 9. P. 1146. doi: 10.3389/fphar.2018.01146.

[31] Harvey PD, Jacobson W, Zhong W. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder. J. Affect. Disord. 2017;15(213):105–111.

[32] Harvey P.D., Jacobson W., Zhong W. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder // J Affect Disord. 2017. Vol. 15. N 213. P. 105–111.

[33] Chen F, Danladi J, Ardalan M. A critical role of mitochondria in bdnf-associated synaptic plasticity after one-week vortioxetine treatment. J Neuropsychopharmacol. 2018;21(6):603–615. doi: 10.1093/ijnp/pyy022.

[34] Chen F., Danladi J., Ardalan M. A critical role of mitochondria in bdnf-associated synaptic plasticity after one-week vortioxetine treatment // J Neuropsychopharmacol. 2018. Vol. 21. N 6. P. 603–615. doi: 10.1093/ijnp/pyy022.

[35] Smagin GN, Song D, Budac DP. Histamine may contribute to vortioxetine’s procognitive effects; possibly through an orexigenic mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2016;(68):25–30. doi: 10.1016/j.pnpbp.2016.03.001.

[36] Smagin G.N., Song D., Budac D.P. Histamine may contribute to vortioxetine’s procognitive effects; possibly through an orexigenic mechanism // Prog Neuropsychopharmacol Biol Psychiatry. 2016. N 68. P. 25–30. doi: 10.1016/j.pnpbp.2016.03.001.

[37] Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord. 2020;263:258–266. doi: 10.1016/j.jad.2019.11.074.

[38] Christensen M.C., Florea I., Loft H., McIntyre R.S. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma // J Affect Disord. 2020. Vol. 263. P. 258–266. doi: 10.1016/j.jad.2019.11.074.

[39] Chen C, Shan W. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: a systematic review and network meta-analysis. Psychiatry Res. 2019;281:112595. doi: 10.1016/j.psychres.2019.112595.

[40] Chen C., Shan W. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: a systematic review and network meta-analysis // Psychiatry Res. 2019. Vol. 281. P. 112595. doi: 10.1016/j.psychres.2019.112595.

[41] Hamilton М. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.

[42] Hamilton М. A rating scale for depression // J Neurol Neurosurg Psychiatry. 1960. Vol. 23. P. 56–62.

[43] Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55.

[44] Hamilton M. The assessment of anxiety states by rating // Br J Med Psychol. 1959. Vol. 32. P. 50–55.

[45] Panteleeva GP, Oleichik IV, Abramova LI, Yumatova PE. Treatment of endogenous depression with venlafaxine: clinical effect, tolerability, and personalized indications. Zhurnal nevrologii i psikhiatrii. 2015;(2):43–51. (In Russ). doi: 10.17116/jnevro20151152243.

[46] Пантелеева Г.П., Олейчик И.В., Абрамова Л.И., Юматова П.Е. Лечение эндогенных депрессий венлафаксином: клиническое действие, переносимость и персонифицированные показания к назначению // Журнал неврологии и психиатрии. 2015. № 2. C. 43–51. doi: 10.17116/jnevro20151152243-51.

[47] Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville; 1976. P. 218–222.

[48] Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology revised. Rockville, 1976. P. 218–222.

[49] Lingjærde O, Ahlfors UG, Bech P. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.

[50] Lingjærde O., Ahlfors U.G., Bech P. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients // Acta Psychiatr Scand Suppl. 1987. Vol. 334. P. 1–100.

[51] Jha MK, Grannemann BD, Trombello JM. A structured approach to detecting and treating depression in primary care: VitalSign6 Project. Ann Fam Med. 2019;17(4):326–335. doi: 10.1370/afm.2418.

[52] Jha M.K., Grannemann B.D., Trombello J.M. A structured approach to detecting and treating depression in primary care: VitalSign6 Project // Ann Fam Med. 2019. Vol. 17. N 4. P. 326–335. doi: 10.1370/afm.2418.

[53] Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol. 2018:269881118788826. doi: 10.1177/0269881118788826.

[54] Christensen M.C., Florea I., Lindsten A., Baldwin D.S. Efficacy of vortioxetine on the physical symptoms of major depressive disorder // J Psychopharmacol. 2018. P. 269881118788826. doi: 10.1177/0269881118788826.

[55] Kazakovtsev BA, Golland VB, Kontsevoy VA, Kozyrev VN, Maksutova AL, Panteleeva GP, et al. Mental and behavioral disorders (F00-F99). (class V ICD-10, adapted for use in the Russian Federation). Part 1. Rostov-on-Don; 1999. 512 p. (In Russ).

[56] Казаковцев Б.А., Голланд В.Б., Концевой В.А., Козырев В.Н., Максутова А.Л., Пантелеева Г.П., и др. Психические расстройства и расстройства поведения (F00-F99) (класс V МКБ-10, адаптированный для использования в Российской Федерации). Ч. 1. Ростов-на-Дону, 1999. 512 с.

[57] Torchinov AM, Bardenshtein LM, Umakhanova MM, Kharkharova MA. Modern aspects of depressive disorders in perimenopausal women. Zhurnal Rossiiskogo obshchestva akusherov-ginekologov. 2006;(3):34–38. (In Russ).

[58] Торчинов А.М., Барденштейн Л.М., Умаханова М.М., Хархарова М.А. Современные аспекты депрессивных расстройств у женщин в перименопаузе // Журнал Российского общества акушеров-гинекологов. 2006. № 3. C. 34–38.

[59] Bardenshtein LM, Piven BN. Comorbid forms of mental illness. Moscow; 2008. 120 р. (In Russ).

[60] Барденштейн Л.М., Пивень Б.Н. Коморбидные формы психических заболеваний. М., 2008. 120 с.

[61] Aleshkina GA, Bardenshtein LM. Acute and transient psychotic disorders. Moscow; 2017. 180 p. (In Russ).

[62] Алешкина Г.А., Барденштейн Л.М. Острые и преходящие психотические расстройства. М., 2017. 180 с.

[63] Bardenshtein LM, Aleshkina GA, Pugacheva ME. Affective disorders in the structure of acute short-term psychoses of the schizophrenic spectrum. Psikhicheskoe zdorov'e. 2019;(3): 44–54. (In Russ).

[64] Барденштейн Л.М., Алешкина Г.А., Пугачева М.Е. Аффективные нарушения в структуре острых кратковременных психозов шизофренического спектра // Психическое здоровье. 2019. № 3. C. 44–54.

[65] Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol. 2018;8(1):13–23. doi: 10.1177/2045125317720642.

[66] Chokka P.R., Hankey J.R. Assessment and management of sexual dysfunction in the context of depression // Ther Adv Psychopharmacol. 2018. Vol. 8. N 1. P. 13–23. doi: 10.1177/2045125317720642.

RIGHTS & PERMISSIONS

Eco-Vector